- Patent Title: Pyrimidines as EGFR inhibitors and methods of treating disorders
-
Application No.: US16950465Application Date: 2020-11-17
-
Publication No.: US11673882B2Publication Date: 2023-06-13
- Inventor: Nathanael S. Gray , Pasi Janne , Hwan Geun Choi , Jaebong Jang
- Applicant: Dana-Farber Cancer Institute, Inc.
- Applicant Address: US MA Boston
- Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee: Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: US MA Boston
- Agency: Lathrop GPM LLP
- Agent Brian C. Trinque; Nicole Sassu
- The original application number of the division: US16290153 2019.03.01
- Main IPC: C07D403/04
- IPC: C07D403/04 ; C07D471/04 ; C07D403/14 ; C07D487/04

Abstract:
The application relates to a compound having Formula (I):
which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
Public/Granted literature
- US20210078977A1 NOVEL PYRIMIDINES AS EGFR INHIBITORS AND METHODS OF TREATING DISORDERS Public/Granted day:2021-03-18
Information query